John R Jones

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

Gordon Cook, David A Cairns, G. Morgan, 2014, Nature Communications.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Gordon Cook, David A Cairns, Matthew Scales, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials.

G. Morgan, W. Gregory, C. Bradbury, 2020, Blood.

Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer

S. Dizdarevic, A. Teagle, G. Burkill, 2016, Nuclear medicine communications.

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.

M. Drayson, M. Jenner, G. Cook, 2022, BMJ open.

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

G. Morgan, W. Gregory, M. Drayson, 2019, The Lancet. Oncology.

Guidelines for the correct determination of second primary malignancies in myeloma trials

G. Morgan, W. Gregory, M. Drayson, 2015 .

Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases

G. Morgan, W. Gregory, M. Drayson, 2015 .

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

M. Drayson, M. Jenner, G. Cook, 2021, BMJ Open.